Damn.. in MY message that I am replying to, I made reference to a company in a PH 3 that is nearing the completion of enrollment. I said NGENF, but what it should have been was NSPR.
I did buy 'some' at $1.14 after I posted that prior one, plan to keep slowly building a position in it, but it has a ways to go before the PH 3 is completed. Thanks to a 1 year 'monitoring' period post enrollment in the trial. Not too thrilled to see the share price moving up, but why I started nibbling was I expect the PH 3 to go as well as the PH 2 did (not a 'complex' development in terms of whether it will 'work' or 'not', cause the PH 3 is essentially an extension of the PH 2)
On a follow up, AVXL did release data from their Ph 2/3 EARLY stage ALZ trial. While the data 'sounds' positive, and the market 'somewhat' liked it (nice pop in the share price), they do need to clarify what they said in terms the market can 'understand' without questioning. And they did surprise late Friday with a release saying they will hold another CC on Monday pre market. So that could get interesting.
(disclaimer: only own 500 shares of AVXL at a cost basis of $8.75/sh) (intention was once the market absorbed the end of the PH 2/3 trial news, planning to keep selling covered calls once the share price settles down. And buy calls for the decision day once the NDA was accepted for review) IF I like the odds of approval. Tho have no idea how to 'put' a value on the shares till they do with what they say.
So reason for posting this was because of the clarification on NSPR and the follow up on AVXL. And note, thought I had all of my ATNM shares taken away at $7.5, but do have 2000 in an account that I had sold $12.5s (Jan expiration) against instead of the Nov $7.5s Will make a decision on whether to hold them come Jan vs keep selling covered calls in a 'take what it gives' mode. But at present, not buying any new ones.
